Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Bibliographic Details
Main Authors:	Nasser K. Altorki, Zachary H. Walsh, Johannes C. Melms, Jeffery L. Port, Benjamin E. Lee, Abu Nasar, Cathy Spinelli, Lindsay Caprio, Meri Rogava, Patricia Ho, Paul J. Christos, Ashish Saxena, Olivier Elemento, Bhavneet Bhinder, Casey Ager, Amit Dipak Amin, Nicholas J. Sanfilippo, Vivek Mittal, Alain C. Borczuk, Silvia C. Formenti, Benjamin Izar, Timothy E. McGraw
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-01-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-023-44575-3

Similar Items

Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
by: Nasser K. Altorki, et al.
Published: (2023-12-01)

Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma
by: Nasser K. Altorki, et al.
Published: (2022-04-01)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Jean-Charles Soria, et al.
Published: (2020-10-01)

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer
by: Jiahao Zhang, et al.
Published: (2025-01-01)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
by: Marie Alt, et al.
Published: (2023-09-01)

Durvalumab-induced triple-M syndrome
by: Femi Williams Adeoye, et al.
Published: (2024-07-01)

Muscle weakness, myositis and scleroderma induced by durvalumab
by: Josu Aguado Suquia, et al.
Published: (2024-12-01)

Durvalumab-associated generalized morphea with overlapping vitiligo
by: Julianna Martel, MD, et al.
Published: (2022-12-01)

Hypoparathyroidism: an uncommon adverse effect of treatment with durvalumab
by: Alexander Kreze, et al.
Published: (2023-01-01)

Strongyloides—An uncommon cause of eosinophilia whilst on durvalumab
by: Gaik Tin Quah, et al.
Published: (2022-10-01)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
by: Shivani Patel, et al.
Published: (2019-12-01)

Phimosis: A rare complication of immunotherapy with durvalumab
by: Luis Gabriel Vázquez-Lavista, et al.
Published: (2020-11-01)

Durvalumab induced sarcoid‐like pulmonary lymphadenopathy
by: Emma Sanderson, et al.
Published: (2020-04-01)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
by: Fitzpatrick O, et al.
Published: (2021-11-01)

Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: a systematic review and meta-analysis
by: Fahmy, Omar, et al.
Published: (2022)

Adverse Events and Tolerability of Combined Durvalumab and Tremelimumab versus Durvalumab Alone in Solid Cancers: A Systematic Review and Meta-Analysis
by: Omar Fahmy, et al.
Published: (2022-05-01)

Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab
by: Erwin H.J. Tonk, et al.
Published: (2019-08-01)

Steroid-unresponsive Immune-mediated Hepatitis Induced by Durvalumab:
by: Omar Sajdeya
Published: (2023-05-01)

Various clinical presentations of uveitis associated with durvalumab treatment
by: Vrabic Nika, et al.
Published: (2022-04-01)

Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
by: Hong Zheng, et al.
Published: (2023-02-01)

Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
by: Alfredo S. Golemba, MD, et al.
Published: (2025-05-01)

Case of durvalumab‐induced annular psoriasiform dermatitis in lung cancer
by: Asako Ota, et al.
Published: (2022-10-01)

Adverse reactions of atezolizumab versus durvalumab based on OpenFDA
by: LU Xinglan, et al.
Published: (2023-09-01)

Durvalumab-Induced Diffuse Alveolar Hemorrhage: An Autopsy Case Report
by: Kensuke Kanaoka, et al.
Published: (2020-06-01)

Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization
by: Maaz Khan Afghan, et al.
Published: (2024-10-01)

Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
by: Narek Shaverdian, et al.
Published: (2020-07-01)

Autoimmune encephalitis following treatment with durvalumab for small-cell lung cancer
by: Yu-Lan Qian, et al.
Published: (2024-10-01)

Durvalumab-associated limbal stem cell deficiency and secondary corneal perforation
by: Nahrain Putris Schumaier, et al.
Published: (2024-09-01)

Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC
by: Paolo Borghetti, et al.
Published: (2022-07-01)

Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
by: J. Capdevila, et al.
Published: (2023-05-01)

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
by: Johan F. Vansteenkiste, MD, PhD, et al.
Published: (2024-03-01)

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1)
by: Jung Wan Choe
Published: (2023-08-01)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
by: Yuhei Kinehara, MD, PhD, et al.
Published: (2023-11-01)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
by: Shuguang Tan, et al.
Published: (2017-05-01)

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
by: Jarushka Naidoo, et al.
Published: (2024-02-01)

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
by: Farastuk Bozorgmehr, et al.
Published: (2020-08-01)

Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
by: Jessica C Hassel, et al.
Published: (2023-06-01)

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations
by: Jason C.S. Ho, et al.
Published: (2024-01-01)

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
by: Zhang C, et al.
Published: (2023-09-01)

Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
by: Farastuk Bozorgmehr, et al.
Published: (2023-08-01)